Form 8-K - Current report:
SEC Accession No. 0001193125-19-235298
Filing Date
2019-08-30
Accepted
2019-08-30 16:10:03
Documents
16
Period of Report
2019-08-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d597711d8k.htm   iXBRL 8-K 34057
2 EX-1.1 d597711dex11.htm EX-1.1 182748
3 EX-5.1 d597711dex51.htm EX-5.1 37871
7 GRAPHIC g597711gra1.jpg GRAPHIC 13942
8 GRAPHIC g597711gra2.jpg GRAPHIC 6905
  Complete submission text file 0001193125-19-235298.txt   459555

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA crsp-20190830.xsd EX-101.SCH 3070
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE crsp-20190830_lab.xml EX-101.LAB 16517
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE crsp-20190830_pre.xml EX-101.PRE 10462
12 EXTRACTED XBRL INSTANCE DOCUMENT d597711d8k_htm.xml XML 3077
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37923 | Film No.: 191069657
SIC: 2836 Biological Products, (No Diagnostic Substances)